Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) picked up nearly 3% IL-17 inhibitor ASC50 US Phase I study achieved positive top-line results

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) recovered by nearly 3%. As of press release, it had risen 2.01% to HK$13.2, with a turnover of HK$31.8424 million.

According to the news, on December 15, Cully Pharmaceutical-B announced that ASC50 achieved positive top-line results in a randomized, double-blind, placebo-controlled phase I clinical trial (NCT07024602) in the US. The trial was a single dose escalation (SAD) study conducted in healthy subjects to evaluate the safety, tolerability, pharmacokinetics, and peripheral circulation of ASC50 to target interleukin-17A (IL-17A) binding characteristics. Forty-six healthy subjects received 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg ASC50, or a matched placebo. The study's goals include evaluating safety, tolerability, pharmacokinetics, and targeted binding effects.

According to reports, ASC50 is an oral small molecule IL-17 targeting inhibitor independently developed by Goli. IL-17 has obtained sufficient biological verification in various autoimmune and inflammatory diseases such as psoriasis and has mature commercial value. ASC50 is a new chemical entity (NCE) with US and global patent protection for compounds until 2043 (excluding potential patent extensions).